DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.
DURECT ([[DRRX]] +3.6%) has dosed the first patient in its AHFIRM Phase 2b study evaluating its lead candidate, DUR-928 in severe alcohol-associated hepatitis ((AH)) patients.In this placebo-controlled 300-subject study, the company will evaluate 90-day survival rate for patients treated with DUR-928 compared to those treated with placebo plus standard of care. Secondary endpoints...
DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients.
Global Transdermal and Transmucosal Drug Delivery Systems Market: Snapshot Transdermal and transmucosal drug delivery systems as alternative drug delivery routes have gained traction in clinical practices over the past few decades. The need for these systems is driven by the growing
DURECT Corporation (Nasdaq: DRRX) today announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience.